Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Expects Core Franchises, Alliances To Strengthen In China

Executive Summary

Merck KGaA's healthcare business in China will continue to center around its fertility, general medicines and endocrinology therapies while also building on new corporate alliances there, the German conglomerate’s global operations head told Scrip. 

 

 

 

 
 

You may also be interested in...



Mavenclad Poised To Be Big Mover For Merck KGaA

The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.

Freshly Funded ImCheck Goes After Gamma Delta T-Cells

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon

Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel